Clinical Trial: Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908641) titled 'Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation' on Oct. 26.

Brief Summary: The main objective of this study is to compare the relative bioavailability, safety, and tolerability of extended-release and immediate-release apremilast formulations in healthy participants.

Study Start Date: Nov. 18

Study Type: INTERVENTIONAL

Condition: Psoriasis Arthritis, Psoriatic Oral Ulcer

Intervention: DRUG: Apremilast XR

Participants will receive apremilast XR orally.

DRUG: Apremilast IR

Participants will receive apremilast IR orally .

Recru...